Summary. The effect of medroxyprogesterone acetate (MPA: Depo‐Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non‐metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non‐hormonal methods of contraception. In the whole group of 84 patients 18 (21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA (9/45) and the oral contraceptive group (2/13) and MPA and the non‐hormonal contraceptive groups (7/26).
|Original language||English (US)|
|Number of pages||4|
|Journal||BJOG: An International Journal of Obstetrics & Gynaecology|
|State||Published - Jan 1987|
ASJC Scopus subject areas
- Obstetrics and Gynecology